Envista Holdings Corp

NYSE:NVST

Medical - Equipment & Services

Healthcare
$23.75 +3.06%

+$0.76 today

Market cap
$3.81B
Beta
0.89
P/E (TTM)
62.0
EPS (TTM)
$0.41
52W Low $18.32High $30.42

Volume 1.92M

Average 2.94M

NVST Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Envista Holdings CorpNYSE: NVST

Gross Margin · Q3 FY2026 · quarter ended Oct 2026

Gross margin widens to 57.9%

Gross margin was 57.9% in Q3 FY2026, up 1.9 pp from a year earlier. On a trailing-twelve-month basis it was 56.0%, up 0.5 pp year over year. Over 3 fiscal years it narrowed by 2.9 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterOct 2026
57.9%+2.2 pp QoQ
Last fiscal yearDec 2025
55.0%-0.4 pp YoY
LTMOct 2026
56.0%+0.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.9 pp——
1 year-0.4 pp——
3 years-2.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
55.0%
Year-over-year change
-0.4pp

Gross Margin vs competitors

How NVST compares with its peers on the latest reported figures

  • NVST's LTM Oct 2026 gross margin of 56.0% is the 3rd highest of the 9 companies compared; the peer median is 33.7%.
  • Its year-over-year change of +0.5 pp is the 5th highest of 9, against a peer median of +0.2 pp.
  • Over three fiscal years its change of -2.9 pp compares with a peer median of +1.3 pp.
NVST Competitors Peer median
Gross Margin for NVST and competitors
Company Period LTM level YoY 3-year change
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202688.1% -0.5 pp+2.7 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
NVSTEnvista Holdings CorpLTM Oct 202656.0% +0.5 pp-2.9 pp
XRAYDENTSPLY SIRONA Inc.LTM Mar 202648.9% -2.6 pp-4.2 pp
ICUIICU Medical, Inc.LTM Jun 202637.6% +1.7 pp+6.2 pp
CONConcentra Group Holdings Parent, Inc.LTM Sep 202629.9% +1.5 pp+4.7 pp
ALHCAlignment Healthcare, Inc.LTM Mar 202612.4% +0.8 pp-0.5 pp
PRVAPrivia Health Group, Inc.LTM Jun 20267.6% -2.2 pp-0.1 pp
GRALGRAIL, Inc.LTM Jun 2026-10.8% +45.7 pp+167.1 pp
APGEApogee Therapeutics, Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
Peer median (excluding NVST) 33.7%+0.2 pp+1.3 pp

Competitors are the stored peer set for NVST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.51B2.57B2.57B2.51B2.72B
Cost of Revenue1.05B1.08B1.12B1.12B1.22B
Gross Profit1.46B1.49B1.45B1.39B1.5B
Gross Margin58.3%57.9%56.5%55.4%55.0%
Research & Development100.5M100.1M93.8M99.1M114M
Selling, General & Admin989.5M1.03B1.03B1.14B1.16B
Operating Expenses1.16B1.17B1.42B2.43B1.27B
Depreciation & Amortization151.9M162.1M162.6M123.1M116M
EBITDA524.3M522M490M279.5M329.8M
EBITDA Margin20.9%20.3%19.1%11.1%12.1%
Operating Income306.2M319.2M31.5M(1.04B)225.7M
Operating Margin12.2%12.4%1.2%-41.4%8.3%
Interest Income00000
Interest Expense54.1M38.4M63.4M46.4M36.6M
Other Income / Expenses(51.7M)(35.3M)(86.4M)(46.5M)(48.5M)
Income Before Tax254.5M283.9M(54.9M)(1.08B)177.2M
Pre-Tax Margin10.1%11.1%-2.1%-43.2%6.5%
Income Tax Expense(9M)45.9M45.3M33.9M130.2M
Net Income340.5M243.1M(100.2M)(1.12B)47M
Net Margin13.6%9.5%-3.9%-44.6%1.7%
EPS (Basic)1.631.46(0.60)(6.50)0.28
EPS (Diluted)1.481.34(0.60)(6.50)0.28
Weighted Avg Shares161.2M162.9M166.9M172.2M168M
Weighted Avg Shares (Diluted)177.6M177.6M166.9M172.2M169.2M

Envista Holdings Corp

NYSE:NVST

Intrinsic Alpha fair value

Locked

Current Price

$23.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.